A study in the journal Circulation: Cardiovascular Quality and Outcomes found patients with nonvalvular atrial fibrillation were more likely to continue taking the anticoagulant dabigatran than warfarin. Researchers examined prescription refills based on claims data for 3,490 people. "We found consistently higher persistence with therapy in those treated with dabigatran at six, nine, and 12 months," the authors wrote.

Related Summaries